Bayer argued that high costs of research could be recovered only through sale proceeds. It also alleged that Natco had not met the preconditions for compulsory licencing.
Staying with the Bombay High Court, foreign drug maker Bayer and generics specialist Natco Pharma sparred over the compulsory licencing issue in court on Tuesday.
Bayer argued that high costs of research could be recovered only through sale proceeds. It also alleged that Natco had not met the preconditions for compulsory licencing.
Bayer also contended no reasonable price for the sale of Nexavar had been specified. Bayer had moved the Bombay High Court, challenging The Intellectual Property Appellate Board's (IPAB)decision to grant Natco a compulsory licence to manufacture a generic version of the cancer drug Nexavar.
Natco Pharma stock price
On April 07, 2014, Natco Pharma closed at Rs 742.45, down Rs 6.5, or 0.87 percent. The 52-week high of the share was Rs 877.00 and the 52-week low was Rs 390.00.
The company's trailing 12-month (TTM) EPS was at Rs 28.47 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 26.08. The latest book value of the company is Rs 160.81 per share. At current value, the price-to-book value of the company is 4.62.
Anda sedang membaca artikel tentang
Bayer, Natco spar at Bombay HC
Dengan url
http://gayafashionshow.blogspot.com/2014/04/bayer-natco-spar-at-bombay-hc.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Bayer, Natco spar at Bombay HC
namun jangan lupa untuk meletakkan link
Bayer, Natco spar at Bombay HC
sebagai sumbernya
0 komentar:
Posting Komentar